Serbia’s pharma sector shifts from supply dependence toward regional growth

Serbia’s pharmaceutical industry is moving beyond a defensive role in meeting domestic healthcare needs, as stronger market growth and improving export performance create a clearer path to regional scale. The shift matters for investors because it combines rising demand drivers with a persistent import gap—an imbalance that can either accelerate local capacity building or expose companies to ongoing procurement pressure.

Trade picture: exports up, deficit still large

In Q1 2026, Serbia exported €172.3m of medicinal and pharmaceutical products, up 15.7% year-on-year. Imports reached €520.0m, down 15.3% from Q1 2025. Despite the improvement, the sector recorded a deficit of €347.7m, compared with €465.3m a year earlier—an indication that local production and export capacity are gaining ground but have not yet closed the gap.

Market expansion: prescription medicines lead value growth

The broader market has also grown quickly. Serbia’s pharmaceutical market reached around €2.07bn in 2025 versus €1.52bn in 2022, implying roughly 36% growth over three years. Prescription medicines were the main driver: the Rx segment added about €137m in new sales, while original prescription medicines accounted for most of the value increase.

Import dependence remains structural

Even with improving exports, Serbia remains a major importer of medicaments. In 2024, imports were about $1.5bn, up from $1.29bn in 2023—the highest level in the available series. Exports were much smaller at about $363m in 2024 after peaking at $444m in 2023.

This structural trade imbalance is central to how investors should interpret the opportunity: there is room for domestic players to capture more value as standards rise and demand grows, but companies still rely heavily on imported inputs and higher-end therapies.

Domestic industrial base and policy support

Serbia has established domestic players—especially Hemofarm (part of STADA), Galenika, Zdravlje Actavis/Teva, PharmaSwiss—and a wider ecosystem of distributors, wholesalers, pharmacies and clinical-service companies. Hemofarm remains the key industrial anchor with production in Vršac and a regional export footprint.

In March 2026, the Serbian government highlighted Hemofarm as a major contributor to economic growth and pointed to further investment in high value-added production—an explicit signal that policymakers want manufacturing depth to expand rather than remain limited to basic supply.

Demand drivers align with regulatory upgrades

The strongest market drivers are clear across both volume and value trends. Serbia’s ageing population is increasing demand for chronic therapies including cardiovascular medicines and diabetes care, alongside oncology, neurology and hospital pharmaceuticals. At the same time, public healthcare spending and reimbursement dynamics are supporting prescription medicine volume growth.

Inflation and higher-value therapies are also lifting market value faster than unit consumption. Beyond domestic factors, Serbia’s CEFTA position provides local manufacturers with access to nearby markets. Meanwhile EU-aligned regulation—including serialization requirements—GMP standards and pharmacovigilance obligations are making Serbian plants more attractive as nearshore production bases.

Where growth may concentrate

The fastest-growing commercial segments are likely to include Rx original medicines, generics, biosimilars, oncology therapies, cardiometabolic treatments, hospital medicines, vaccines and biologics distribution—as well as consumer health products such as supplements and private-label pharmacy offerings.

Generics remain important because cost control is needed within Serbia’s healthcare system, while originals and specialty therapies continue to drive value expansion.

Investment case extends beyond drug manufacturing

For investors, the opportunity is not limited to producing drugs. It also spans contract manufacturing; packaging; cold-chain logistics; pharma warehousing; clinical trials; regulatory affairs; pharmacovigilance; quality-control labs; medical distribution; and digital pharmacy infrastructure.

The investment logic rests on Serbia’s cost base, scientific talent pool, regional access and industrial tradition—but it also acknowledges constraints: the sector still depends heavily on imported APIs (active pharmaceutical ingredients), advanced biologics, specialty medicines and patented therapies.

A developing platform for regional production

The 2026 thesis is therefore straightforward: Serbia may not yet be a large pharmaceutical power globally, but it is becoming more important as a regional production and distribution platform aligned with growing healthcare demand. The market is expanding, imports remain high though improving trade dynamics suggest momentum in exports, and local manufacturing has enough industrial depth to capture more value if Serbia continues moving into high-standard generics and biosimilars as well as sterile production capabilities like packaging, testing and regional supply-chain services.